Cannabis-based treatments show the strongest evidence for MS pain and spasticity
A review of clinical studies found that cannabis-based treatments, particularly nabiximols oromucosal spray and oral cannabinoids, consistently reduced pain and spasticity in multiple sclerosis patients.
Quick Facts
What This Study Found
Nabiximols (oromucosal spray) demonstrated improvement in MS spasticity, pain, and quality of life with tolerable adverse effects. Oral cannabinoids were significantly effective for MS pain and spasticity. Evidence for other MS symptoms like tremors, ataxia, and bladder dysfunction was inconsistent.
Key Numbers
Two main delivery routes reviewed: oromucosal spray (nabiximols) and oral cannabinoids. Both showed positive effects on pain and spasticity. Other symptoms showed only slight improvement with inconsistent evidence.
How They Did This
Review of clinical studies investigating cannabis effects on MS symptoms including spasticity, pain, tremors, ataxia, bladder functions, sleep, quality of life, and adverse effects.
Why This Research Matters
MS patients frequently report using cannabis for symptom relief. This review helps clarify which symptoms have the strongest supporting evidence and which delivery methods appear most effective.
The Bigger Picture
Pain and spasticity remain the best-supported indications for cannabinoid treatment in MS, while the evidence for other common MS symptoms remains weak, suggesting clinicians should set realistic expectations.
What This Study Doesn't Tell Us
Review scope and methodology not fully detailed. Evidence for symptoms beyond pain and spasticity described as inconsistent. Study quality of included trials varies.
Questions This Raises
- ?Why does cannabis appear to help MS pain and spasticity but not other neurological symptoms?
- ?Could different cannabinoid ratios or delivery methods improve outcomes for tremor or bladder dysfunction?
Trust & Context
- Key Stat:
- Pain and spasticity: consistent benefit. Other MS symptoms: inconsistent evidence.
- Evidence Grade:
- Review of multiple clinical studies with generally positive findings for pain and spasticity but inconsistent evidence for other outcomes.
- Study Age:
- Published in 2022.
- Original Title:
- The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms.
- Published In:
- Life (Basel, Switzerland), 12(5) (2022)
- Authors:
- Haddad, Fatma, Dokmak, Ghadeer, Karaman, Rafik(2)
- Database ID:
- RTHC-03898
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does cannabis help with MS symptoms?
The strongest evidence supports cannabis for MS-related pain and spasticity, particularly using nabiximols spray or oral cannabinoids. Evidence for tremors, bladder dysfunction, and other symptoms was inconsistent.
What form of cannabis works best for MS?
Both nabiximols (oromucosal spray) and oral cannabinoids showed significant effects on pain and spasticity, with nabiximols also improving quality of life scores.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03898APA
Haddad, Fatma; Dokmak, Ghadeer; Karaman, Rafik. (2022). The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms.. Life (Basel, Switzerland), 12(5). https://doi.org/10.3390/life12050682
MLA
Haddad, Fatma, et al. "The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms.." Life (Basel, 2022. https://doi.org/10.3390/life12050682
RethinkTHC
RethinkTHC Research Database. "The Efficacy of Cannabis on Multiple Sclerosis-Related Sympt..." RTHC-03898. Retrieved from https://rethinkthc.com/research/haddad-2022-the-efficacy-of-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.